(-0.03%) 5 476.75 points
(-0.04%) 38 803 points
(0.01%) 19 923 points
(0.29%) $80.56
(1.11%) $2.82
(0.11%) $2 331.60
(-0.36%) $29.29
(-0.13%) $969.60
(0.02%) $0.932
(-0.12%) $10.64
(0.08%) $0.788
(-1.87%) $86.80
Live Chart Being Loaded With Signals
Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The company is headquartered in Blue Ash, Ohio and currently employs 27 full-time employees...
Stats | |
---|---|
Šios dienos apimtis | 826 006 |
Vidutinė apimtis | 401 776 |
Rinkos kapitalizacija | 53.67M |
EPS | $-0.860 ( Q3 | 2023-09-30 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
0 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.177 (8.05%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2021-06-30 | Dalal Anupam | Buy | 7 400 | Common Stock |
2021-06-30 | Castelein Caley | Buy | 7 811 | Common Stock |
2021-06-30 | Cohen Cheryl | Buy | 8 140 | Common Stock |
2021-06-17 | Cohen Cheryl | Buy | 100 000 | Stock Option (Right to Buy) |
2021-03-31 | Cohen Cheryl | Buy | 8 020 | Common Stock |
INSIDER POWER |
---|
0.00 |
Last 63 transactions |
Buy: 4 252 497 | Sell: 3 402 072 |
Tūris Koreliacija
Aerpio Pharmaceuticals Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Aerpio Pharmaceuticals Koreliacija - Valiuta/Žaliavos
Aerpio Pharmaceuticals Finansinės ataskaitos
Annual | 2022 |
Pajamos: | $5.51M |
Bruto pelnas: | $-29.51M (-535.75 %) |
EPS: | $-1.080 |
FY | 2022 |
Pajamos: | $5.51M |
Bruto pelnas: | $-29.51M (-535.75 %) |
EPS: | $-1.080 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Aerpio Pharmaceuticals
Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The company is headquartered in Blue Ash, Ohio and currently employs 27 full-time employees. The firm is focused on developing treatments for ocular disease. Its lead product candidate is AKB-9778. Its other two pipeline programs include AKB-4924 and ARP-1536. AKB-9778 is a small molecule activator of the Tie-2 pathway, which is being developed for the treatment of diabetic retinopathy (DR). AKB-4924 is a selective stabilizer of hypoxia-inducible factor-1 alpha (HIF-1alpha), which is being developed for the treatment of inflammatory bowel disease (IBD). ARP-1536 is a humanized monoclonal antibody directed at the same target as AKB-9778. ARP-1536 binds the extracellular domain of vascular endothelial protein tyrosine phosphatase (VE-PTP) inhibiting its ability to interact with Tie-2. As of April 14, 2017, the Company had completed a Phase II trial of AKB-9778 in 144 patients with diabetic macular edema. As of April 14, 2017, the Company had completed Phase Ia clinical trial in healthy volunteers for AKB-4924.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.